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Abstract
Background: Influenza is an important cause of morbidity and mortality for frail older people. Whilst the antiviral drug
oseltamivir (a neuraminidase inhibitor) is approved for treatment and prophylaxis of influenza during outbreaks, there have
been no trials comparing treatment only (T) versus treatment and prophylaxis (T&P) in Aged Care Facilities (ACFs). Our
objective was to compare a policy of T versus T&P for influenza outbreaks in ACFs.
Methods and Findings: We performed a cluster randomised controlled trial in 16 ACFs, that followed a policy of either
‘‘T’’—oseltamivir treatment (75 mg twice a day for 5 days)—or ‘‘T&P’’—treatment and prophylaxis (75 mg once a day for 10
days) for influenza outbreaks over three years, in addition to enhanced surveillance. The primary outcome measure was the
attack rate of influenza. Secondary outcomes measures were deaths, hospitalisation, pneumonia and adverse events.
Laboratory testing was performed to identify the viral cause of influenza-like illness (ILI) outbreaks. The study period 30 June
2006 to 23 December 2008 included three southern hemisphere winters. During that time, influenza was confirmed as the
cause of nine of the 23 ILI outbreaks that occurred amongst the 16 ACFs. The policy of T&P resulted in a significant
reduction in the influenza attack rate amongst residents: 93/255 (36%) in residents in T facilities versus 91/397 (23%) in T&P
facilities (p = 0.002). We observed a non-significant reduction in staff: 46/216 (21%) in T facilities versus 47/350 (13%) in T&P
facilities (p = 0.5). There was a significant reduction in mean duration of outbreaks (T = 24 days, T&P = 11 days, p = 0.04).
Deaths, hospitalisations and pneumonia were non-significantly reduced in the T&P allocated facilities. Drug adverse events
were common but tolerated.
Conclusion: Our trial lacked power but these results provide some support for a policy of ‘‘treatment and prophylaxis’’ with
oseltamivir in controlling influenza outbreaks in ACFs.
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Introduction
Influenza is a cause of significant morbidity and mortality [1],
with the highest hospitalisation rates in the very young and the
very old. In developed countries, the majority of deaths
attributable to influenza occur in people aged over 65 years,
especially those over 80 years with pre-existing health problems
and residents of Aged Care Facilities (ACFs) [1]. Attack rates of
20–40% may occur in ACF outbreaks and are associated with
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increased rates of hospitalisation and death [2,3]. The elderly may
also shed influenza virus at higher levels and for longer duration
than younger adults [4,5,6]. As a result, transmission to others is
more likely. In addition, accentuated transmission of influenza
within closed institutions is a recognised problem, which results in
significant morbidity and costs [7,8,9].
Immunisation against influenza is recommended for high-risk
populations in Australia including all persons aged 65 years and
over [10]. Vaccination is less effective in the elderly [11], and
influenza outbreaks have been documented in highly vaccinated
ACF populations, where the intensity of transmission appears to
override vaccine-conferred immunity [2]. Thus, additional strat-
egies such as the use of antiviral therapy need to be considered.
Although oseltamivir is effective for treating and preventing
influenza [12,13], strategies of oseltamivir use in outbreaks,
namely treatment alone, or treatment together with prophylaxis,
have never been compared head to head. As frail institutionalised
elderly are disproportionately affected by influenza outbreaks (yet
rarely included in randomised controlled trials [14]), we decided to
evaluate the effectiveness of these two different strategies in a
cluster-randomised controlled clinical trial. We chose to randomly
assign the strategies by facility, rather than by individual, because
influenza is a communicable disease that once introduced into a
facility can be readily transmitted, and because the use of
oseltamivir to treat patients in an outbreak may result in ‘‘herd
protective effects’’ beyond an individual effect.
Our aim was to test the hypothesis that a policy of treatment
and prophylaxis with oseltamivir would be a more effective than
treatment only. Our results provide some support for this
hypothesis.
Methods
Ethics statement
The study was approved by the Ethics Committees of The
University of Sydney and The Children’s Hospital at Westmead.
As oseltamivir was used in a currently approved manner in
Australia, the study did not come under the Guardianship
Tribunal legislation for clinical trials.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The cluster randomised controlled trial was a
collaboration between The University of Sydney and Moran
Health Care Group, the largest private provider of aged care
facilities in Australia. The 16 ACFs owned and managed by the
Moran Health Care Group within the greater metropolitan region
of Sydney were asked to participate and all agreed.
The two different management policies used in the cluster RCT
were:
Table 1. Baseline characteristics of influenza outbreak aged care facilities by treatment allocation.
Baseline characteristic
T&P outbreak
facilities (n=6)
T outbreak
facilities (n =3) Two-tailed p value
Mean number of residents 66 85 0.33
Mean number of beds in facility 86 89 0.91
Mean number of individual staff 58 72 0.51
Mean (median) time between ILI onset in the first case and
declaration of outbreak (days)
5.0 (5) 12.7 (12) 0.06
Mean number of cases in residents prior to declaration of outbreak 5.7 12 0.08
Mean number of cases in staff prior to declaration of outbreak 4 5 0.67
doi:10.1371/journal.pone.0046509.t001
Table 2. Baseline characteristics of consented residents in outbreak versus non-outbreak facilities.
Consented residents with baseline data (n=905)
Outbreak Facilities Non-Outbreak Facilities
T T&P
T versus P p
value
Non-Outbreak
facilities
Outbreak vs Non-
outbreak p value
Number 77 314 514
Mean age 80.7 81.5 0.51 81.8 0.08
Female: Male 1.7 2.4 0.17 1.6 0.11
(n) (48:29) (221:93) (131:79)
Mean number of co-morbidities 4.5 4.9 0.07 4.9 0.64
Mean weight (kg) 62.8 61.7 0.57 60.9 0.49
Influenza immunisation received
during the autumn vaccination period
immediately preceding the influenza
outbreak (if known) %
83.6% 84.8% 0.95 81.1% 0.70
(N) (46/55) (251/296) (340/419)
doi:10.1371/journal.pone.0046509.t002
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Table 3. A comparison of the baseline characteristics of consented staff who were involved in the nine influenza outbreaks
compared to those in facilities with no confirmed influenza outbreaks.
Consented staff (no. =275)
Outbreak Facilities Non-outbreak facilities
T T&P T versus P p value
Non-Outbreak
facilities
Outbreak vs Non-
outbreak p value
Number 20 154 101
Mean age 43.27 47.09 0.34 43.80 0.12
Female: Male 9.0 10.8 0.82 8.8 0.68
(n) (18:2) (140:13) (88:10)
Mean number of co-
morbidities
2.20 1.70 0.11 1.94 0.61
Influenza immunisation
received during the
autumn vaccination
period immediately
preceding the influenza
outbreak (if known)
50% 34.8% 0.41 27.4% 0.36
(n) (9/18) (49/141) (17/62)
doi:10.1371/journal.pone.0046509.t003
Figure 1. Flow diagram of progress of clusters and individuals in the trial.
doi:10.1371/journal.pone.0046509.g001
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Treatment only (T): A policy of using oseltamivir for treatment
of both residents and staff with test-confirmed influenza and also
residents and staff with influenza-like illness (ILI) that were
epidemiologically linked by being resident in, or working in, the
same wing or floor of the ACF as a test-confirmed case of
influenza.
Treatment and Prophylaxis (T&P): A policy of using oseltamivir
for treatment of individuals as specified above PLUS prophylaxis
of consenting individuals who were resident in, or working in the
same wing or floor of the ACF as a test-confirmed case of
influenza.
Pre-specified outcomes
The primary pre-specified outcome was the attack rate of
influenza in the ‘‘T’’ versus the ‘‘T&P’’ ACFs (confirmed, probable
and possible influenza cases) in residents and staff of ACFs during
outbreaks of influenza. Secondary outcomes were: case fatality rate
within 4 weeks from onset of an outbreak; pneumonia incidence in
subjects within 4 weeks from onset of influenza symptoms; hospital
admission incidence within 4 weeks from onset of influenza
symptoms; adverse events within 4 weeks of commencing
oseltamivir; and outbreak duration (defined as the date of the
onset of the first symptomatic resident in a confirmed influenza
outbreak to the date of onset of the last case).
Oseltamivir dosing regimens
Treatment. Oseltamivir 75 mg orally twice daily for 5 days
was offered to all persons with influenza diagnosed within
48 hours from the onset of symptoms, by point-of-care test or
laboratory testing, and persons who met the clinical definition for
ILI and whose symptoms had duration of less than 48 hours when
an outbreak of influenza infection was identified in their ACF.
Prophylaxis. Oseltamivir 75 mg orally once daily for 10 days
was offered to all staff and resident of T&P ACFs when an
influenza outbreak was identified in their ACF.
The oseltamivir dose interval was doubled for participants with
known renal impairment (creatinine clearance 10 to 30 ml/min).
Sample size
To obtain 80% power at 2-sided 5% significance level for
detecting a significant difference of attack rate between the two
interventions (T, T&P), and for an assumed 10% (or 15%) attack
rate in the T arm and 3% (or 6%) in the T&P arm, a sample size of
8 clusters (ACFs) or 360 subjects per arm was required for cluster
size (m) 45 and intra-cluster correlation coefficient (ICC) 0.02 [15].
The intra-cluster correlation coefficient value was calculated on
the basis of cases of clinical respiratory illness in a previous cluster
randomised clinical trial of personal protection masks [16]. The
design effect (deff) for this cluster randomization trial was 1.88
(deff = 1+(m21)6ICC=1+(4521)60.02= 1.88). As such, we
aimed to recruit a sample size of 8 ACFs per arm.
Random assignment of ACFs to oseltamivir use strategy
1. The ACFs were stratified by architecture type due to the
possible influence of building design on infection transmission:
Figure 2. Epidemic curve for the influenza outbreak in Treatment only (‘‘T’’) Aged Care Facility A (confirmed and probable cases,
amongst residents and staff).
doi:10.1371/journal.pone.0046509.g002
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N Type A: old dormitory style, multi-storey, non-purpose-built
ACFs with communal toilets and bathrooms (making these
facilities ‘more crowded’)
N Type B: modern single-level purpose-built ACFs with
adjoining assisted-living apartments (ALAs – low-level care
independent living units) at the same site, with some shared
facilities, staff and resident movements
N Type C: modern single-level purpose-built ACFs without
adjoining ALA
2. A third-party researcher assigned participating ACFs (within
each stratum) to one of the oseltamivir use strategies by using a
computerized stratified random process.
ACF and study staff were not blinded once random allocation
was generated.
Inclusion criteria for individuals
Any resident or staff member of a participating ACF was eligible
to receive the intervention randomly assigned to the facility,
provided individual written consent was obtained from the subject
or the subject’s guardian/legal representative (when dementia or
other incapacity was present).
Exclusion criteria for individuals
Exclusion criteria were known allergy to oseltamivir, symptoms
of influenza for more than 48 hours, pregnancy, and end-stage
renal disease or a creatinine clearance estimated to be 10 ml/min
or less.
Other influenza control strategies during the trial
The research team reminded each participating ACF to
implement the influenza prevention measures recommended at
the time by the Australian Government Department of Health and
Ageing and New South Wales Health Department, for the
prevention of influenza outbreaks in ACFs [17]. These measures
include annual influenza vaccination of residents and staff, and
standard infection control practices for respiratory infections
(including hand washing, protective equipment and isolation), and
restricting access to the facility.
Definitions of: ILI, ILI outbreak and influenza outbreak
An ILI case was defined as acute onset of fever $38uC, with
acute cough or any other respiratory sign or symptom in a resident
or staff member. An ILI outbreak was defined as two ILI cases
over a three day period, or, three ILI cases over a seven day
period. An influenza outbreak was defined as an ILI outbreak with
at least one ILI case having influenza virus detected by point of
care testing, direct immunofluorescence or nucleic acid testing.
Training of selected ACF staff in ILI surveillance and
testing for influenza
Research team members visited participating ACFs in order to
explain the study to staff. At each ACF, selected ACF staff
Figure 3. Epidemic curve for the influenza outbreak in Treatment only (‘‘T’’) Aged Care Facility B (confirmed and probable cases,
amongst residents and staff).
doi:10.1371/journal.pone.0046509.g003
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members agreed to be ILI surveillance officers for that facility and
were trained in active ILI surveillance and were provided with and
trained in the use of the point of care testing [18].
ILI surveillance
In order to identify as many ILI outbreaks as possible during the
study period, a system of active influenza surveillance was
instituted [18]. During influenza seasons study staff telephoned
ACF ILI surveillance officers three times each week. At other times
when influenza was not active in the community, the telephone
calls were made once-weekly. At each call ACF ILI surveillance
officers were asked to report the number of residents and staff who
had ILI. If any ILI cases were reported at an ACF, the frequency
with which study staff telephoned that facility increased to daily
until either an ILI outbreak was identified or until 8 days had
passed since the last ILI case.
Identification of influenza outbreaks
ACF ILI surveillance officers performed influenza A and B
specific point of care tests on ILI cases after consent had been
obtained. If this identified influenza in a facility or if outbreaks of
ILI were identified without a positive point of care test, the study
team investigated the outbreak. The study team consisted of
physicians, nurses and epidemiologists. This team performed an
epidemiological investigation to determine the outbreak’s aetiol-
ogy, its spread and what control measures had to be taken. If an
influenza outbreak was confirmed, residents and staff were treated
from the date of declaration according to the oseltamivir usage
policy assigned to that ACF, and the research team emphasised
compliance with the infection control policy [17].
Influenza case definitions
We defined a confirmed influenza case as an ILI case with
identification of an influenza virus by point of care test, direct
immunofluorescence or nucleic acid testing, culture or a $4-fold
rise in complement fixing antibody titres. A probable influenza
case was defined as an ILI case in the same floor or wing as a
confirmed influenza case and who was either not tested for
influenza or was tested but had negative results. A possible
influenza case was defined as a person with respiratory signs and
symptoms without fever who was in the same floor or wing as a
confirmed influenza case and who was either not tested for
influenza or was tested but had negative results.
Identification of the ‘first case’ in each outbreak
We sought to identify the ‘first case’ in each ILI outbreak by
establishing an apparent sequence of transmission. We identified
all persons (staff or residents) who had respiratory symptoms and
who were resident or working within an isolatable unit (e.g. the
wing or floor of the ACF) in which an outbreak was occurring.
Their dates of symptom onset were determined and ranked in date
order. For influenza outbreaks, their symptoms were classified
according to the probable and possible influenza case definitions
and an apparent sequence of transmission was accepted when
there was no more than three days between the onset dates of a
probable influenza case and the previous probable influenza case.
Figure 4. Epidemic curve for the influenza outbreaks in Treatment only (‘‘T’’) Aged Care Facility C (confirmed and probable cases,
amongst residents and staff).
doi:10.1371/journal.pone.0046509.g004
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Data collected (influenza outbreaks)
Data collected for each consented subject was: the category of
person who had ILI (i.e. staff versus resident), date of birth, age,
sex, room occupied (resident) or main work area (staff) within the
ACF, co-morbidities, medications, influenza vaccinations in the
last 3 years, pneumococcal vaccination in the last 5 years, ILI
onset date, measured body temperature, presence and duration of
respiratory signs and symptoms, possible adverse events, hospital-
isation details, pneumonia, death, general practitioner visits, plus
data arising from diagnostic samples collected during the study.
Diagnostic samples (influenza outbreaks)
When an influenza outbreak was declared, swabs were collected
from the nose and throat of each consenting resident and staff
member who either had ILI or was eligible to receive prophylaxis.
The swabs were transported to the laboratory at 4uC in viral
transport medium. In addition, acute and convalescent serum
samples were collected 4 to 6 weeks apart.
Laboratory methods
Nose and throat swabs samples were collected from individuals
with ILI for point of care testing (QuickVue Influenza A+B Test;
Quidel Corp., San Diego, CA., USA) [19]. Direct immunofluo-
rescence was performed using cells from nose and throat swabs
spotted on glass slides. The cells were acetone-fixed and stained
with fluorescein-conjugated monoclonal antibodies (Chemicon
International, Temecula, CA, USA) against influenza A and B and
other respiratory viruses (adenoviruses, parainfluenzaviruses and
respiratory syncytial virus) [20]. Nucleic acid testing was
performed using a nested reverse transcriptase polymerase chain
reaction for influenza A and B on RNA extracted from the nose
and throat samples using the High Pure viral RNA kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to the
manufacturer’s instructions [21].
Influenza virus isolation (culture) was undertaken in MDCK
cells. After 4 days incubation (35uC) the cells were stained with
fluorescent influenza A & B monoclonal antibodies (SimulFluor
FluA/FluB MoAb, Light Diagnostics, Temecula, CA, USA). Virus
subtyping was performed by the WHO Collaborating Centre for
Reference and Research on Influenza (Melbourne, Victoria,
Australia) on a sub-set of isolates.
Influenza A- and influenza B-specific complement fixing
antibody titres were determined on acute and convalescent sera
in parallel, with definitive influenza recorded if there was a four-
fold or greater rise in titres [20].
Calculated values
In comparisons of baseline characteristics of ACF (Table 1),
consented residents (Table 2) and staff (Table 3), we used (1) Two-
sample t-test for continuous data with normal distribution, (2)
Wilcoxon’s Rank Sum Test for continuous variables with non-
normal distribution, and (3) Two-sample Chi-square Test for
binomial data. SPSS Version 19 (IBM, USA)[Computer Software]
was used for these calculations.’’
Figure 5. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility D (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g005
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As each influenza outbreak occurred in a different ACF, facility-
level observations can be assumed to be independent. The primary
outcome of attack rate was analysed using Poisson regression, with
the count of number of influenza cases per facility regressed on
treatment group, and the number of residents within each facility
incorporated as an offset to allow for variation in facility size.
Negative binomial regression was used where Poisson models
showed greater than expected variability in counts arising from
clustering. The secondary outcomes of attack rate in staff, resident
deaths during outbreak and cases of chest infection and
pneumonia were analysed in the same way. Due to problems
with model convergence, hospitalisation of residents was analysed
using the exact Wilcoxon test. Outbreak duration was also
analysed using the exact Wilcoxon test. The randomisation test
was used to obtain exact p-values [22].
Mathematical modeling of influenza outbreaks
Mathematical modelling was undertaken to investigate the
spread of influenza within ACFs under different assumptions of
susceptibility. This had the advantage of providing sensitivity
analyses for the main results. The model assumed a pool of
susceptibles comprising all residents and staff of each ACF where
an outbreak occurred. Before the epidemic, a proportion of the
susceptibles are ‘‘removed’’, by virtue of immunity from either
prior vaccination or infection. The model assumes that individuals
go through an incubation period of d days before they are
recorded in the epidemic curve, such that individuals who are
recorded as symptomatic on day t were infected on day t2d.
Individuals develop both infectivity and symptoms following
infection. The relative infectivity of each case was assumed to
increase initially and then decrease so as to give a mean serial
interval of 2.6 days. The expected number of infections on each
day is calculated from the force of infection, taking into account
the depletion of the pool of susceptibles.
Without intervention, the force of infection operating in an ACF
on each day of an epidemic is determined from the number of
people infected on each of the preceding days, multiplied by an
unknown constant h. In the period after intervention, h is replaced
with hT for T ACFs, and hTP for T&P ACFs. The three constants
(h, hT and hTP) were determined by statistical analysis: a likelihood
function was used to compare the expected number of infections
on each day with the observed number of infections. A statistically
significant difference between h and hT or hTP indicates an effect
of the intervention. The efficacies of the interventions were defined
as 12hT/h (for treatment only) and 12hTP/h (for treatment &
prophylaxis), so that an efficacy of 100% means that transmission
is totally interrupted by the intervention.
The infectiousness and disease profile from Ferguson was
adapted and simplified [23]. We assumed a mean incubation
period of 1 day, and a mean serial interval of 2.6 days between
cases. We considered there were too many uncertainties to build a
model incorporating the prevalence of pre-existing strain specific
immunity among residents or staff due to vaccination and previous
exposure, so as a sensitivity analysis, we tested assumptions that
that 50%, 75% or 100% of patients and staff were initially
susceptible to influenza. For further sensitivity analysis, we re-
Figure 6. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility E (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g006
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analysed the data under assumptions that the incubation period
was 0, 1 or 2 days, and that the serial interval was 2.2, 2.6 or 3.2
days.
Results
We recruited 16 ACFs in the Greater Metropolitan Area of
Sydney, Australia and the trial was carried out between 30 June
2006 and 23 December 2008, covering three southern hemisphere
influenza seasons. The flow of participants is shown in Figure 1.
The baseline characteristics of the ACFs with influenza outbreaks
allocated T and those allocated T&P were not statistically
significantly different (Table 1).
Of 23 ILI outbreaks identified: nine (39%) were due to influenza
viruses; two (9%) were caused by respiratory syncytial virus; two
(9%) by parainfluenzaviruses, one (4%) rhinovirus; and nine (39%)
had no confirmed viral agent. Three of the influenza outbreaks
occurred in T ACFs (Figures 2, 3, 4) and six in T&P facilities
(Figures 5, 6, 7, 8, 9,10). The numbers of residents for each
outbreak was determined by the layout and architecture of the
facility and by the actual occupancy of the facility at the time of the
outbreak.
Despite significant attempts to obtain consent from/for
residents in advance of anticipated influenza seasons, consent
usually had to be obtained during the influenza outbreaks. If an
outbreak was identified in a T facility, for logistical reasons, only
the residents and staff with ILI were approached for consent.
However, in T&P facilities consent was required from/for anyone
receiving treatment or prophylaxis. The baseline characteristics of
consented individuals within each randomised facility were similar
in the ‘‘T’’ and ‘‘T&P’’ facilities (Tables 2 and 3, Figure 1). During
the actual outbreaks, in T&P facilities, 318 out of 397 (80%) of the
residents and 194/350 (55%) of the staff consented to receive the
oseltamivir to deliver the randomised policy. In T facilities 64 out
of 255 (25%) of the residents and 18 out of 216 (8%) of the staff
consented to receive oseltmivir in order to deliver the randomised
policy. Of note, these ACFs had good coverage of influenza
vaccination in the preceding autumn, with rates of 84% and 85%
for ‘‘T’’ and ‘‘T&P’’ ACFs respectively.
Of the nine confirmed outbreaks, one occurred in 2006 (a T&P
ACF), five occurred in 2007 (3 T&P ACFs; 2 T ACFs) which was a
severe epidemic year [24], and three in 2008 (2 T&P and 1 T).
The mean (median) time from onset of ILI in the first case to the
declaration of an outbreak was 12.7 (12) and 5.0 (5) days
respectively in T vs T&P ACFs (p=0.06) and the mean number of
cases in residents prior to declaration of the influenza outbreak was
12 in the T ACFs and 5.7 in the T&P ACFs, p = 0.08 (Table 1).
The allocated policy was applied to all outbreaks but in ACF B (a
treatment only allocated facility) the local Public Health Unit
(PHU) commenced additional prophylaxis of residents late in the
outbreak.
The mean duration of influenza outbreaks was 15.2 days (range
8 to 37); 10.8 days in the T&P ACFs compared to 24 days in the T
ACFs (p = 0.03). Excluding the outbreak in ACF B (where the
Public Heath Unit converted the treatment allocation into T&P),
Figure 7. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility F (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g007
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the mean outbreak duration of the 2 remaining T ACFs was 26
days.
The observed attack rate in residents was significantly lower in
T&P facilities compared to T facilities (Rate Ratio 0.63 95%
Confidence Interval 0.47 to 0.84, p = 0.002), with an observed
attack rate of 36.5% in T ACFs compared to 22.9% in T&P ACFs.
The reduction in attack rate amongst staff was non-significant
(Rate Ratio 0.71 95% CI 0.26 to 1.93, p = 0.5), with an attack rate
of 21.3% versus 13.4%, respectively. In exploratory post hoc
sensitivity analyses, the trial intervention was also significant when
analysed by attack rates confined to confirmed and probable
influenza cases (Figure 11). However, the results were insignificant
when confined to confirmed influenza cases only. Confirmed
influenza cases in residents were 19.6% (T only) versus 10.8%
(T&P), p = 0.08; and in staff 3.2% (T only) versus 4.6% (T&P),
p = 0.4.
We identified concurrent co-circulation of two different
influenza viruses in 4 of the 9 outbreaks (see Table 4). The
secondary outcomes of hospitalisation, death, pneumonia alone
and pneumonia plus chest infection (of all types) in residents were
all non-significantly reduced in the T&P facilities (Table 4), and
irrespective of whether ACF B is included.
Adverse drug reactions
None of the residents or staff stopped taking the prescribed
oseltamivir due to adverse events. Adverse events were reported in
23.1% for those prescribed oseltamivir for treatment (data
available for 108 residents) and 10.4% for those prescribed
oseltamivir for prophylaxis (data available for 250 residents). Rates
of adverse events for residents who received oseltamivir for
treatment were: headache 7%; vomiting 5%; vertigo/dizziness 3%
and nausea 2%. Rates for residents who took oseltamivir for
prophylaxis were: headache 2%; vomiting 2%; vertigo/dizziness
2%; and nausea 3%.
Adverse events were reported in 76% of staff who took
oseltamivir for treatment (data available from 21 staff) and 28%
for those who took oseltamivir for prophylaxis (data available from
137 staff).
Adverse event rates for the staff who took oseltamivir for
treatment were: headache 48%, nausea 29%, vertigo/dizziness
19% and vomiting 10%. Adverse event rates for staff who took
oseltamivir for prophylaxis were: headache 15%, nausea 15%,
vomiting 6% and vertigo/dizziness 4%.
Mathematical modeling
Under the various assumptions investigated in the mathematical
modeling, the T&P intervention strategy is predicted to reduce the
number of transmission events attributable to each case by a
significant amount. The T strategy was effective under the
assumptions in the Base Case and also if a long serial interval or
low degree of prior immunity was assumed. In every case, the
median estimate of the efficacy of T was outside the 95%
Figure 8. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility G (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g008
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Confidence Interval of the efficacy for T&P, indicating that T&P
was more effective for preventing transmission (Table 5).
Discussion
These results provide evidence that supports a policy of routine
oseltamivir treatment and prophylaxis for residents and staff
during proven influenza outbreaks in aged care facilities.
Treatment and prophylaxis was associated with a reduced attack
rate, and a non-significant reduction in secondary outcomes. Our
results support recent guideline statements advocating such a
policy [25]. Previously, Schilling et al demonstrated in a pilot study
that zanamivir appeared promising when used in a large ACF in
the United States, but to our knowledge further trials have not
been attempted with this or other neuraminidase inhibitors [26].
Strengths of our study include the prospective cluster-rando-
mised controlled trial design run over three influenza seasons. Our
active surveillance and detailed epidemiological investigation of
potential outbreaks led to far more influenza outbreaks being
detected than usually reported in New South Wales. Our sample
size assumptions proved rather optimistic given we stated that we
expected to see attack rates of 10% (or 15%) attack rate in the T
arm and 3% (or 6%) in the T&P arm. The higher than expected
rates in both arms could have arisen for many different reasons:
our detailed investigations might have revealed the true attack
rates in ACF outbreaks; the style of nursing may have contributed
as all our facilities were under the same management company; or
perhaps our enhanced education and infection control sessions
with facility staff were not as successful as we hoped. An important
unanticipated result from our study was that influenza was only
responsible for a minority of ILI outbreaks with 14 out of 23
respiratory illness outbreaks being due to other viruses (or no
aetiological agent identified). More expansive nucleic acid testing
may have identified the other viral causes of outbreaks; only direct
immunofluorescence was used to detect a limited range of
respiratory viruses as the interventions were directed to confirmed
influenza outbreaks. Our results suggest that ‘‘Point of care
testing’’ and laboratory confirmation of influenza or other
respiratory virus infections is important in the investigation of
ILI outbreaks in ACFs, and it is unwise to assume that all ILI
outbreaks in ACFs are due to influenza.
The non-significant reduction in our secondary pre-specified
outcome measures (deaths, hospitalisations and chest infections in
residents) provide additional reassurance that the policy of
treatment and prophylaxis is appropriate. These results was
achieved despite our inability to treat all ‘‘at risk’’ residents and
staff due to the constraints of the trial design (some declined
consent) and the practicalities of treatment (some residents and
staff were not eligible for treatment). The research design,
including the requirement for individual informed consent possibly
limited the proportion of residents and staff who accepted the
Figure 9. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility H (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g009
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interventions, and it is possible that greater coverage with
oseltamivir prophylaxis would achieve greater protection.
The weaknesses of our trial were the low number of influenza
outbreaks (nine) and the play of chance on randomisation, with
influenza outbreaks occurring in three T ACFs and six T&P ACFs.
Recruitment of more nursing homes, and thus clusters, would have
helped balance randomization but this was not feasible given our
funding and partnership with the ACF provider. The limited
number of outbreaks reduced the power of the trial, especially for
the secondary outcomes, which whilst generally in favour of the
T&P policy, did not reach statistical significance. We recognise
that our trial was underpowered as our main results were not
confirmed in some of our sensitivity analyses, given the limited
number of randomised facilities with outbreaks during the study.
The imbalance of outbreaks amongst the two cluster randomised
groups did not lead to statistically significant differences between
the baseline variables of the outbreak characteristics or residents
but the delay in declaring the outbreak in the T only facilities, and
corresponding increase in the number of residents who were sick
at the time of the implementation of the trial intervention could
have contributed to the positive result of the trial. The imbalance
in the number of residents and staff consented was due to the
requirement of written informed consent for all residents who
would be offered treatment. In T facility outbreaks, residents
without symptoms did not need to be treated (or tested) and were
therefore not approached for consent during an outbreak. In T&P
facilities, we were required to obtain consent in all eligible
residents in order to deliver the prophylactic arm of the trial.
Despite attempts to consent all residents prior to outbreaks, the
turnover of residents and huge workload required, meant that we
were only able to consent a minority prior to an outbreak. Given
that this differential consent rate could have potentially identified
more people with subclinical influenza in the T&P facilities, we
may have underestimated the effectiveness of a policy of T&P.
Our experience emphasizes the need for careful planning and
investment to rapidly establish a treatment and prophylaxis
intervention during outbreaks. In the trial, numerous extra
research staff (up to ten) were enlisted during outbreaks yet it
was often 2–3 days before it was possible to complete prophylaxis
of all at-risk consented residents and staff. Some of the most time
consuming duties may be lessened in routine clinical practice, such
as a written consent process. However, other tasks would remain
difficult to achieve quickly, such as assessing the renal function of
every resident, and establishing whether they, or their legal
guardians wished treatment to be given, unless this had been
determined beforehand as recommended [25]. The lack of
blinding in our study could have created bias in case ascertain-
ment, but a double-blind study would probably be unfeasible, or at
least prohibitively expensive.
Our mathematical modeling of transmission also showed a
substantial reduction in the reproduction number in the T&P
facilities, relative to the T facilities. This reduction is due to
Figure 10. Epidemic curves for the influenza outbreak in Treatment and Prophylaxis (‘‘T & P’’) Aged Care Facility I (confirmed and
probable cases, amongst residents & staff).
doi:10.1371/journal.pone.0046509.g010
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decreased susceptibility of prophylaxed patients, and decreased
infectivity of breakthrough and undetected cases. The basic
reproduction number for influenza is assumed to be 2 (or less) in
the general population although it may be much higher in
modified communities such as ACFs. After allowing for some prior
immunity and vaccination, it seems plausible that a reduction in
transmission of 70% would be required to explain the containment
of the epidemics in the T&P group.
We acknowledge the difficulty of conducting trials in ACFs,
and, in retrospect, the resources required to undertake the trial
were underestimated. As a result of our unexpected difficulties in
establishing the intervention, some of the planned data collection
was not possible. Given the low power of our study, we believe that
further research to confirm these results would be important.
What are the implications of this study for routine public health
policy? We believe that public health departments should explore
the feasibility and benefits of introducing an active surveillance
approach for ILI in ACFs during at risk periods such as winter.
This could be done by telephone or electronic communication,
and centralised for a large number of nursing facilities. The
potential advantage of early diagnosis and treatment may not only
prevent unpleasant symptoms and illness for residents but also for
their carers, including staff and relatives. Laboratory confirmation
of outbreaks will also allow a clearer understanding of the clinical
features and outcomes of non-influenza virus outbreaks in the frail
elderly. Our observation of multiple viral outbreaks occurring
simultaneously within an ACF and the concurrent illness of staff
suggest that ACFs provide an important focus of viral infection in
winter months and a possible mechanism of maintaining infection
in the community. Even if the potential benefits to residents of
reducing the burden of illness is discounted, control of infection in
ACFs may be an important public health intervention for the
wider community. Although deaths amongst younger people such
as the staff of ACFs are rare, they have been reported [2]. We
would argue that infection control, including antiviral treatment, is
important.
Our results need to be considered in the light of reports of
oseltamivir resistance, and increased resistance will clearly
attenuate the effectiveness of a T&P policy [27]. As the more
widespread use of prophylaxis could increase resistance, surveil-
lance for influenza A subtypes and oseltamivir resistance in local
geographic areas is important [28]. On the other hand, our results
provide indirect support that the use of other antiviral medication
for treatment AND prophylaxis might be an effective policy for
ACFs.
An important point is that data on drug efficacy and safety is
rarely available for the frail vulnerable patient: this trial is a step
forward in providing some evidence for those in ACFs. With our
ageing populations, many millions of people are cared for in such
institutions and it is important to establish the risks and benefits of
interventions for this population who are usually excluded in
medical research. We appreciate the difficulties in conducting
trials for such populations but we hope that others will also
consider studies involving the frail older resident of ACFs.
Figure 11. Number of incident cases (confirmed+probable) per 100 people (residents & staff) in T and T&P ACFs.
doi:10.1371/journal.pone.0046509.g011
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Table 5. Mathematical modeling.
Assumed fraction with prior
immunity Strategy
Efficacy (% reduction) median
estimate Efficacy (95% credibility interval)
25% Treatment 45 (23, 61)
T & P 72 (56, 83)
50% Treatment 30 (5, 50)
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